Extended-release niacin with or without a statin improves lipid profile in patients with type II diabetes

Extended-release niacin, alone o r combined with a statin agent, significantly improved dyslipidemia in patients with type II diabetes with only minimal impact on blood glucose control, according to an article in the July 21st issue of the Archives of Internal Medicine. The study, the largest of its kind conducted with niacin, highlights
the therapeutic utility of extended-release preparations in managing lipid abnormalities in this patient population with an extremely high cardiovascular risk.

The Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial (ADVENT), involved 146 patients: During the 16-week trial, 49 patients were randomized to placebo, whereas 45 received 1000 mg niacin daily and 52 received 1,500 mg niacin daily. Of the total, 69 patients (47 percent) were also receiving a statin agent, usually atorvastatin.

In dose-dependent manner, niacin increased high-density lipoprotein cholesterol by as much as 24 percent and reduced levels of triglycerides by as much as 36 percent compared with placebo.

These improvements were achieved with minimal impact on glucose control as measured by fasting blood glucose and hemoglobin A1c: There was no significant difference in fasting glucose among the three patient groups. There was no significant difference between the lower-dose niacin group and the placebo group in levels of hemoglobin A1c, and the increase in hemoglobin A1c level for the higher-dose niacin group was only 0.03 percent at 16 weeks, which just reach statistical significance.

Rates of adverse effects were the same among all groups except for flushing, which was more common in niacin patients. No patient experienced elevated liver enzymes greater than three times the upper limit of the reference range. There were no reports of drug-induced myopathy, even among patients also taking a statin drug.

"Approximately 97% of people with diabetes have at least one lipid abnormality, therefore effective dyslipidemia treatment is an important consideration for diabetic patients, who are at great risk of heart disease," said Scott M. Grundy, M.D., Ph.D., principal investigator of the study. "The ADVENT study is significant for people with diabetic dyslipidemia because we now know that low doses of niacin can effectively
treat lipid abnormalities in these patients."







DOLについて - 利用規約 -  会員規約 -  著作権 - サイトポリシー - 免責条項 - お問い合わせ
Copyright 2000-2025 by HESCO International, Ltd.